Literature DB >> 20846039

The humoral response to HIV-1: new insights, renewed focus.

Galit Alter1, M Anthony Moody.   

Abstract

During the past 2 decades, significant advances in our understanding of the humoral immune response to human immunodeficiency virus type 1 (HIV-1) infection have been made, yet a tremendous amount of work lies ahead. Despite these advances, strategies to reliably induce antibodies that can control HIV-1 infection are still critically needed. However, recent advances in our understanding of the kinetics, specificity, and function of early humoral responses offer alternative new approaches to attain this goal. These results, along with the new broadly neutralizing antibody specificities, the role for other antibody functions, the increased understanding of HIV-1-induced changes to B cell biology, and results from the RV144 "Thai" trial showing potential modest sterilizing protection by nonneutralizing antibody responses, have renewed focus on the humoral system. In this review, recent advances in our understanding of the earliest humoral responses are discussed, highlighting presentations from the meeting on the Biology of Acute HIV Infection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20846039      PMCID: PMC2945610          DOI: 10.1086/655654

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  63 in total

1.  Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region.

Authors:  Elin S Gray; Maphuti C Madiga; Penny L Moore; Koleka Mlisana; Salim S Abdool Karim; James M Binley; George M Shaw; John R Mascola; Lynn Morris
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

2.  Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles.

Authors:  Miroslaw K Gorny; Leonidas Stamatatos; Barbara Volsky; Kathy Revesz; Constance Williams; Xiao-Hong Wang; Sandra Cohen; Robert Staudinger; Susan Zolla-Pazner
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

3.  Isolation of antigen-binding cells from unprimed mice. II. Evidence for monospecificity of antigen-binding cells.

Authors:  M H Julius; C A Janeway; L A Herzenberg
Journal:  Eur J Immunol       Date:  1976-04       Impact factor: 5.532

Review 4.  The mucosal immune system: primary target for HIV infection and AIDS.

Authors:  R S Veazey; P A Marx; A A Lackner
Journal:  Trends Immunol       Date:  2001-11       Impact factor: 16.687

5.  Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1.

Authors:  Donald N Forthal; Gary Landucci; Tran B Phan; Juan Becerra
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

6.  Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence.

Authors:  W J Honnen; C Krachmarov; S C Kayman; M K Gorny; S Zolla-Pazner; A Pinter
Journal:  J Virol       Date:  2006-11-22       Impact factor: 5.103

7.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

8.  Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.

Authors:  J P Moore; Y Cao; L Qing; Q J Sattentau; J Pyati; R Koduri; J Robinson; C F Barbas; D R Burton; D D Ho
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

9.  Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection.

Authors:  Penny L Moore; Nthabeleng Ranchobe; Bronwen E Lambson; Elin S Gray; Eleanor Cave; Melissa-Rose Abrahams; Gama Bandawe; Koleka Mlisana; Salim S Abdool Karim; Carolyn Williamson; Lynn Morris
Journal:  PLoS Pathog       Date:  2009-09-18       Impact factor: 6.823

10.  The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?

Authors:  Rafick-Pierre Sekaly
Journal:  J Exp Med       Date:  2008-01-14       Impact factor: 14.307

View more
  20 in total

Review 1.  Boosting vaccine efficacy the natural (killer) way.

Authors:  Carolyn E Rydyznski; Stephen N Waggoner
Journal:  Trends Immunol       Date:  2015-08-10       Impact factor: 16.687

2.  Evolution of the Envelope Glycoprotein of HIV-1 Clade B toward Higher Infectious Properties over the Course of the Epidemic.

Authors:  Laurence Meyer; Francis Barin; Mélanie Bouvin-Pley; Maxime Beretta; Alain Moreau; Emmanuelle Roch; Asma Essat; Cécile Goujard; Marie-Laure Chaix; Nathalie Moiré; Loïc Martin; Martine Braibant
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

3.  A Partial E3 Deletion in Replication-Defective Adenoviral Vectors Allows for Stable Expression of Potentially Toxic Transgene Products.

Authors:  Larissa H Haut; Amanda L Gill; Raj K Kurupati; Ang Bian; Yan Li; Wynetta Giles-Davis; Zhiquan Xiang; Xiang Yang Zhou; Hildegund C J Ertl
Journal:  Hum Gene Ther Methods       Date:  2016-09-07       Impact factor: 2.396

4.  A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays.

Authors:  Michael D Alpert; Lisa N Heyer; David E J Williams; Jackson D Harvey; Thomas Greenough; Maria Allhorn; David T Evans
Journal:  J Virol       Date:  2012-08-29       Impact factor: 5.103

5.  HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques.

Authors:  Michael A Thomas; Iskra Tuero; Thorsten Demberg; Diego A Vargas-Inchaustegui; Thomas Musich; Peng Xiao; David Venzon; Celia LaBranche; David C Montefiori; Janet DiPasquale; Steven G Reed; Anthony DeVico; Timothy Fouts; George K Lewis; Robert C Gallo; Marjorie Robert-Guroff
Journal:  Virology       Date:  2014-10-28       Impact factor: 3.616

Review 6.  Role of IL-21 and IL-21 receptor on B cells in HIV infection.

Authors:  Suresh Pallikkuth; Anita Parmigiani; Savita Pahwa
Journal:  Crit Rev Immunol       Date:  2012       Impact factor: 2.214

7.  Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes.

Authors:  Thushan I de Silva; Marlén Aasa-Chapman; Matthew Cotten; Stéphane Hué; James Robinson; Frederic Bibollet-Ruche; Ramu Sarge-Njie; Neil Berry; Assan Jaye; Peter Aaby; Hilton Whittle; Sarah Rowland-Jones; Robin Weiss
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

8.  A High Throughput Protein Microarray Approach to Classify HIV Monoclonal Antibodies and Variant Antigens.

Authors:  Emmanuel Y Dotsey; Andrea Gorlani; Sampat Ingale; Chad J Achenbach; Donald N Forthal; Philip L Felgner; Johannes S Gach
Journal:  PLoS One       Date:  2015-05-04       Impact factor: 3.240

9.  The Broad Neutralizing Antibody Responses after HIV-1 Superinfection Are Not Dominated by Antibodies Directed to Epitopes Common in Single Infection.

Authors:  Valerie Cortez; Bingjie Wang; Adam Dingens; Mitchell M Chen; Keshet Ronen; Ivelin S Georgiev; R Scott McClelland; Julie Overbaugh
Journal:  PLoS Pathog       Date:  2015-07-09       Impact factor: 6.823

10.  ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge.

Authors:  Michael D Alpert; Jackson D Harvey; W Anderson Lauer; R Keith Reeves; Michael Piatak; Angela Carville; Keith G Mansfield; Jeffrey D Lifson; Wenjun Li; Ronald C Desrosiers; R Paul Johnson; David T Evans
Journal:  PLoS Pathog       Date:  2012-08-23       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.